Literature DB >> 16439016

JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.

Vidya Udupi1, Margaret Yu, Swati Malaviya, Joseph E Saavedra, Paul J Shami.   

Abstract

Nitric oxide (NO) induces differentiation and apoptosis in acute myelogenous leukemia (AML) cells. The NO prodrug O2-(2,4-dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate, or JS-K, has potent antileukemic activity. JS-K induces apoptosis in HL-60 cells by a caspase-dependent mechanism. The purpose of this study was to determine the pathway through which JS-K induces apoptosis. We show that JS-K alters mitochondrial membrane potential (DeltaPsim) and induces cytochrome c release from mitochondria into the cytoplasm. Treatment with JS-K resulted in activation of Caspase (Casp) 9, Casp 3 and Casp 8. JS-K constitutes a promising lead for a new class of anti-leukemic agents.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16439016     DOI： 10.1016/j.leukres.2005.12.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  20 in total

1.  JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.

Authors:  Vanity McMurtry; Joseph E Saavedra; René Nieves-Alicea; Ann-Marie Simeone; Larry K Keefer; Ana M Tari
Journal:  Int J Oncol       Date:  2011-01-25       Impact factor: 5.650

2.  Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO.

Authors:  Steven Hutchens; Yefim Manevich; Lin He; Kenneth D Tew; Danyelle M Townsend
Journal:  Invest New Drugs       Date:  2010-03-16       Impact factor: 3.850

3.  Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.

Authors:  Harinath Chakrapani; Michael M Goodblatt; Vidya Udupi; Swati Malaviya; Paul J Shami; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem Lett       Date:  2008-01-04       Impact factor: 2.823

4.  Exogenous NO induces apoptosis of hepatocellular carcinoma cells via positive p38/JNK signaling pathway and negative ERK signaling pathways.

Authors:  Ling Liu; Yihao Xing; Mengyao Cao; Jinglei Xu; Jingjing Chen
Journal:  Mol Cell Biochem       Date:  2021-01-09       Impact factor: 3.396

5.  Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.

Authors:  Varun Kumar; Sam Y Hong; Anna E Maciag; Joseph E Saavedra; Douglas H Adamson; Robert K Prud'homme; Larry K Keefer; Harinath Chakrapani
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

6.  Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.

Authors:  Monika Z Kaczmarek; Ryan J Holland; Stephen A Lavanier; Jami A Troxler; Valentyna I Fesenkova; Charlotte A Hanson; Joan L Cmarik; Joseph E Saavedra; Larry K Keefer; Sandra K Ruscetti
Journal:  Leuk Res       Date:  2013-12-12       Impact factor: 3.156

7.  Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Authors:  Daniela Andrei; Anna E Maciag; Harinath Chakrapani; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

8.  Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.

Authors:  Jie Liu; Swati Malavya; Xueqian Wang; Joseph E Saavedra; Larry K Keefer; Erik Tokar; Wei Qu; Michael P Waalkes; Paul J Shami
Journal:  Genomics       Date:  2009-04-05       Impact factor: 5.736

9.  Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.

Authors:  Harinath Chakrapani; Ravi C Kalathur; Anna E Maciag; Michael L Citro; Xinhua Ji; Larry K Keefer; Joseph E Saavedra
Journal:  Bioorg Med Chem       Date:  2008-09-30       Impact factor: 3.641

10.  JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1.

Authors:  Kornelia Edes; Pamela Cassidy; Paul J Shami; Philip J Moos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.